Andrew Penman to join the Southern Research Institute as Vice President of Drug Development

Life Science Partner recruits former Vice President, Preclinical Development for Angiotech and Aptuit.

Life Science Partner announces the recruitment of Andrew Penman, an experienced scientist and preclinical development executive, to the Southern Research Institute in Birmingham, Alabama.  Southern Research Institute is an independent, not-for-profit center for scientific research providing innovative leadership in scientific discovery and drug development.  With a focus on the discovery and advancement of new, small-molecule therapeutics from the design stage to the clinic, Southern Research Institute’s Drug Discovery Research Division has accomplished innovative research in the areas of cancer, infectious disease and neuroscience.

Most recently, Penman was the Vice President of Preclinical Development for Angiotech, a global specialty pharmaceutical and medical device company, where he was responsible for managing the global preclinical business in research and development for the company.  Previously, Penman served as President of Preclinical Technologies at Aptuit (formerly Quintiles, Inc).  In his role at the Southern Research Institute, he will be responsible for providing scientific vision, strategic direction and operational management of the Drug Development Division of the Institute.

“Penman is a talented preclinical pharmaceutical development executive with broad experience in infectious diseases, oncology and cardiology drugs,” noted Tom Callaway, President of Life Science Partner.  “He will successfully build upon the Institute’s considerable scientific expertise and drug development platform and further enhance their reputation as one of the nation’s premier drug discovery organizations.”

Penman received his undergraduate degree in Chemistry from the Heriot-Watt University in Edinburgh, Scotland and earned his PhD from the University of Kent in Canterbury, Kent.